# Vaccination of Triple Negative Breast Cancer Patients

> **NCT02938442** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 16 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Breast Neoplasms

## Interventions

- **BIOLOGICAL:** P10s-PADRE with MONTANIDE™ ISA 51 VG
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02938442
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-25
- **Primary completion:** 2023-01-09
- **Final completion:** 2023-01-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02938442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02938442, "Vaccination of Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02938442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*